Molecular mechanism of action for reversible P2Y12 antagonists

被引:9
|
作者
Liu, Haibo [2 ]
Ge, Hu [1 ]
Peng, Yong [2 ]
Xiao, Peigen [2 ]
Xu, Jun [1 ]
机构
[1] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China
[2] Chinese Acad Med Sci, Peking Union Med Coll, Inst Med Plant Dev, Beijing 100194, Peoples R China
关键词
P2Y(12) receptor; ADP; Antagonists; Platelets aggregation; SWISS-MODEL REPOSITORY; CLOPIDOGREL PLUS ASPIRIN; ANTIPLATELET THERAPY; RECEPTOR ANTAGONIST; COST-EFFECTIVENESS; P2; RECEPTORS; FREE-ENERGY; PROTEIN; PREVENTION; P2Y12;
D O I
10.1016/j.bpc.2011.03.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recently, reversible antagonists of the P2Y(12) receptor have been reported. However, the mechanisms of binding have not been elucidated. To this end, a number of homology models were built by means of three programs from four templates. A consensus model was derived from those initial models. The final model was created by refining the consensus model with molecular dynamics simulations. The agonist and antagonists of P2Y(12) have been docked in the final model. For the agonist, the Arg256, Lys280, and Phe252 are "hot" residues. For the antagonists, the Lys280 and Phe252 are "hot" residues that have hydrogen bonding contacts and pi-pi interactions, respectively. These results can explain the observations of mutation experiments and can guide the design of new inhibitors. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:74 / 81
页数:8
相关论文
共 50 条
  • [1] New P2Y12 antagonists
    Michelson, Alan D.
    CURRENT OPINION IN HEMATOLOGY, 2009, 16 (05) : 371 - 377
  • [2] Mode of action of P2Y12 antagonists as inhibitors of platelet function
    Iyu, David
    Glenn, Jackie R.
    White, Ann E.
    Fox, Sue C.
    van Giezen, Hans
    Nylander, Sven
    Heptinstall, Stan
    THROMBOSIS AND HAEMOSTASIS, 2011, 105 (01) : 96 - 106
  • [3] Mode of action of P2Y12 antagonists as inhibitors of platelet function
    Glenn, J.
    Iyu, D. E.
    White, A. E.
    Fox, S. C.
    van Giezen, H.
    Nylander, S.
    Heptinstall, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 319 - 320
  • [4] Preclinical and clinical studies with selective reversible direct P2Y12 antagonists
    van Giezen, JJJ
    Humphries, RG
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2005, 31 (02): : 195 - 204
  • [5] The future of P2Y12 receptor antagonists
    Thomas, Mark R.
    Storey, Robert F.
    PLATELETS, 2015, 26 (05) : 392 - 398
  • [6] The P2Y12 Antagonists, 2MeSAMP and Cangrelor, Inhibit Platelet Activation through P2Y12/Gi-Dependent Mechanism
    Xiang, Binggang
    Zhang, Guoying
    Ren, Hongmei
    Sunkara, Manjula
    Morris, Andrew J.
    Gartner, T. Kent
    Smyth, Susan S.
    Li, Zhenyu
    PLOS ONE, 2012, 7 (12):
  • [7] Molecular modeling of purinergic receptor P2Y12 and interaction with its antagonists
    Zhan, Chenyang
    Yang, Jie
    Dong, Xian-Chi
    Wang, Yue-Lan
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2007, 26 (01): : 20 - 31
  • [8] State of the art of new P2Y12 antagonists
    Marco Cattaneo
    Gian Marco Podda
    Internal and Emergency Medicine, 2010, 5 : 385 - 391
  • [9] Multiple electrode aggregometry and P2Y12 antagonists
    Johnson, Andrew
    Dovlatova, Natalia
    Heptinstall, Stan
    THROMBOSIS AND HAEMOSTASIS, 2008, 99 (06) : 1127 - 1129
  • [10] State of the art of new P2Y12 antagonists
    Cattaneo, Marco
    Podda, Gian Marco
    INTERNAL AND EMERGENCY MEDICINE, 2010, 5 (05) : 385 - 391